What question did this study set out to answer?

To explore the role of JAK inhibitors in juvenile dermatomyositis with an elevated IFN signature.

December 19, 2025Open Access

Towards New Strategies: Case Report and Review of the Literature: Effective Application of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis

View Full Paper

Ask AI

Bookmark

To explore the role of JAK inhibitors in juvenile dermatomyositis with an elevated IFN signature.
Case report of a 4-year-old boy with juvenile dermatomyositis and anti-MDA5 antibodies
Introduced baricitinib as a steroid-sparing treatment
Monitored clinical outcomes, including skin and muscle involvement
Marked clinical improvement noted after baricitinib introduction
Resolution of skin lesions and normalization of MDA5 antibodies
Pronounced reduction in IFN signature observed

No takes yet. Share an insight, caveat, or question.

Case report demonstrates baricitinib's efficacy for juvenile dermatomyositis, suggesting improvements with immunosuppressive therapy.

Buzoianu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark